文献速递肝病

瞬时弹性成像可准确筛查持续或近期戒酒患者的代偿期进展性慢性肝病

Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients With Ongoing or Recent Alcohol Withdrawal.
PubMed 文献 · Clin Gastroenterol Hepatol · 2021-02-12

这项前瞻性研究在法国6家成瘾治疗中心纳入259例因酒精戒断住院且AST升高的患者,在戒酒后中位6天行瞬时弹性成像(TE)并与肝活检比较。TE在入组时及1、2个月随访时排除酒精相关代偿期进展性慢性肝病(cACLD)的AUC分别为0.96、0.96和0.93;肝硬度<10 kPa可排除cACLD(阴性预测值99%),>25 kPa可确诊(阳性预测值93%)。

要点

  • 戒酒后2个月内行TE可高精度排除酒精相关cACLD。
  • 肝硬度<10 kPa排除cACLD的阴性预测值为99%。
  • 肝硬度>25 kPa诊断cACLD的阳性预测值为93%。

核心结论

  • 戒酒后前2个月内进行的TE是排除酒精相关cACLD的优良方法。
  • 基于转氨酶和/或胆红素的算法未增加TE在该期间的诊断效能。

研究设计与样本

  • 前瞻性研究,在法国6家住院成瘾中心招募因酒精戒断住院、转氨酶升高且无显性肝硬化病史或体征的患者。
  • 符合方案分析纳入259例患者,TE、组织学和生化检测在戒酒后中位6天完成,TE和生化在1个月和2个月后重复。

主要发现

  • 259例中45例(17%)存在cACLD。
  • TE在入组时及1、2个月随访的AUC分别为0.96(95%CI 0.94-0.99)、0.96(95%CI 0.92-0.99)和0.93(95%CI 0.85-1.00)。
  • 84%的患者中,肝硬度<10 kPa可排除cACLD(阴性预测值99%,95%CI 98%-100%),>25 kPa可确诊cACLD(阳性预测值93%,95%CI 83%-102%)。
  • 初始肝硬度10-25 kPa且无cACLD的患者中,超过半数在1个月和2个月随访时肝硬度<10 kPa。

关键数值与推荐

  • 肝硬度<10 kPa排除cACLD的阴性预测值为99%(95%CI 98%-100%)。
  • 肝硬度>25 kPa诊断cACLD的阳性预测值为93%(95%CI 83%-102%)。

临床怎么用

  • 对因酒精戒断住院且转氨酶升高的患者,可在戒酒后2个月内行TE以排除cACLD。
  • 肝硬度<10 kPa可基本排除cACLD,>25 kPa可支持cACLD诊断。
  • 初始肝硬度10-25 kPa者可在1-2个月后重复TE,部分患者肝硬度可降至10 kPa以下。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Liver stiffness measurement by transient elastography (TE) is a promising method for staging fibrosis in alcohol-related liver disease, but uncertainties remain regarding the influence of alcohol consumption and thus the ideal timing for TE performance. We evaluated the performance of TE compared with liver biopsy to exclude compensated advanced chronic liver disease (cACLD) in patients hospitalized for alcohol detoxification. METHODS: Patients were recruited prospectively at 6 in-patient addiction centers in France. Eligible patients had increased aspartate aminotransferase levels, and no history or signs of overt cirrhosis. TE, histology, and biochemistry measurements were obtained within a median of 6 days after alcohol withdrawal. TE and biochemistry were repeated 1 and 2 months later. RESULTS: The study included 259 patients for per-protocol analysis, of whom 45 (17%) had cACLD. TE identified patients with high accuracy at inclusion and at the 1- and 2-month follow-up evaluation, with area under the curve values of 0.96 (95% CIs, 0.94-0.99), 0.96 (95% CIs, 0.92-0.99), and 0.93 (95% CIs, 0.85-1.00), respectively. In 84% of patients, cACLD was ruled out when liver stiffness was less than 10 kPa (negative predictive value, 99% (95% CIs, 98%-100%)) or ruled in when greater than 25 kPa (positive predictive value, 93% (95% CI, 83%-102%)). Algorithms based on aminotransferase levels and/or bilirubin did not add to the diagnostic performance of TE in this period. Among patients with initial liver stiffness of 10 to 25 kPa, more than half of those with no cACLD showed liver stiffness of less than 10 at 1- and 2-month follow-up testing. CONCLUSIONS: TE performed during the first 2 months after alcohol cessation is an excellent method for excluding alcohol-related cACLD. CLINICAL TRIAL NUMBER: NCT01789008.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Legros L, Bardou-Jacquet E, Turlin B, et al. Transient Elastography Accurately Screens for Compensated Advanced Chronic Liver Disease in Patients With Ongoing or Recent Alcohol Withdrawal. Clin Gastroenterol Hepatol. 2021. PMID: 33588101. doi:10.1016/j.cgh.2021.02.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。